Conditioning the whole heart-not just the cardiomyocyte

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 1, 2012, Pages 24-32

  Bell, Robert M ^a   Yellon, Derek M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardiac myocyte; Endothelium; Fibroblast; Postconditioning; Preconditioning; Remote conditioning

Indexed keywords

ADIPONECTIN; BRADYKININ B2 RECEPTOR; CARDIOTROPHIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FIBROBLAST GROWTH FACTOR 2; GROWTH DIFFERENTIATION FACTOR 15; HEME OXYGENASE; HYDROGEN SULFIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; PROTEIN KINASE B; STROMAL CELL DERIVED FACTOR 1ALPHA; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA;

BLOOD FLOW; CELL PROTECTION; CELL VIABILITY; CORONARY ARTERY BLOOD FLOW; ENDOTHELIUM CELL; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; FIBROBLAST; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; PERCUTANEOUS CORONARY INTERVENTION; PERICYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REPERFUSION INJURY; REVASCULARIZATION; REVIEW; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIUM; MYOCYTES, CARDIAC;

EID: 84861961823     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.04.001     Document Type: Review

References (117)

1. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med Nov 2006, 3(11):e442.
2. Butler M.J., Chan W., Taylor A.J., Dart A.M., Duffy S.J. Management of the no-reflow phenomenon. Pharmacol Ther Oct 2011, 132(1):72-85.
3. Kloner R.A. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther Sep 2011, 16(3-4):244-250.
4. Schwartz B.G., Kloner R.A. Coronary no reflow. J Mol Cell Cardiol 2012, 52:873-882.
5. Rezkalla S.H., Dharmashankar K.C., Abdalrahman I.B., Kloner R.A. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol Oct 2011, 23(5):429-436.
6. Hausenloy D.J., Lecour S., Yellon D.M. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal Mar 1 2011, 14(5):893-907.
7. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med Sep 13 2007, 357(11):1121-1135.
8. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation Nov 1986, 74(5):1124-1136.
9. Shi W., Vinten-Johansen J. Endogenous Cardioprotection by Ischaemic Postconditioning and Remote Conditioning. Cardiovasc Res 2012, 94:206-216.
10. Hausenloy D.J., Yellon D.M. The therapeutic potential of ischemic conditioning: an update. Nat Rev Nov 2011, 8(11):619-629.
11. Yang X., Cohen M.V., Downey J.M. Mechanism of cardioprotection by early ischemic preconditioning. Cardiovasc Drugs Ther Jun 2010, 24(3):225-234.
12. Cohen M.V., Downey J.M. Ischemic postconditioning: from receptor to end-effector. Antioxid Redox Signal Mar 1 2011, 14(5):821-831.
13. Boengler K., Hilfiker-Kleiner D., Drexler H., Heusch G., Schulz R. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther Nov 2008, 120(2):172-185.
14. Goto M., Liu Y., Yang X.M., Ardell J.L., Cohen M.V., Downey J.M. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res Sep 1995, 77(3):611-621.
15. Anversa P., Olivetti G., Melissari M., Loud A.V. Stereological measurement of cellular and subcellular hypertrophy and hyperplasia in the papillary muscle of adult rat. J Mol Cell Cardiol Aug 1980, 12(8):781-795.
16. Vliegen H.W., van der Laarse A., Cornelisse C.J., Eulderink F. Myocardial changes in pressure overload-induced left ventricular hypertrophy. A study on tissue composition, polyploidization and multinucleation. Eur Heart J 1991, 12(4):488-494.
17. Nag A.C., Zak R. Dissociation of adult mammalian heart into single cell suspension: an ultrastructural study. J Anat Oct 1979, 129(Pt 3):541-559.
18. Banerjee I., Fuseler J.W., Price R.L., Borg T.K., Baudino T.A. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Sep 2007, 293(3):H1883-H1891.
19. Brutsaert D.L. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev Jan 2003, 83(1):59-115.
20. Nag A.C. Study of non-muscle cells of the adult mammalian heart: a fine structural analysis and distribution. Cytobios 1980, 28(109):41-61.
21. Cai Z., Manalo D.J., Wei G., Rodriguez E.R., Fox-Talbot K., Lu H., et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation Jul 8 2003, 108(1):79-85.
22. Bullard A.J., Govewalla P., Yellon D.M. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol Sep 2005, 100(5):397-403.
23. Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest Oct 2003, 112(7):999-1007.
24. Teng R., Calvert J.W., Sibmooh N., Piknova B., Suzuki N., Sun J., et al. Acute erythropoietin cardioprotection is mediated by endothelial response. Basic Res Cardiol May 2011, 106(3):343-354.
25. Amann K., Wiest G., Zimmer G., Gretz N., Ritz E., Mall G. Reduced capillary density in the myocardium of uremic rats-a stereological study. Kidney Int Nov 1992, 42(5):1079-1085.
26. Henquell L., Odoroff C.L., Honig C.R. Intercapillary distance and capillary reserve in hypertrophied rat hearts beating in situ. Circ Res Sep 1977, 41(3):400-408.
27. Brutsaert D.L., De Keulenaer G.W., Fransen P., Mohan P., Kaluza G.L., Andries L.J., et al. The cardiac endothelium: functional morphology, development, and physiology. Prog Cardiovasc Dis Nov-Dec 1996, 39(3):239-262.
28. SJ O., Zellner J.L., Cox M.H., Hebbar L., Brothers T.E., Mukherjee R., et al. Contributory mechanisms for the beneficial effects of myocyte preconditioning during cardioplegic arrest. Circulation 1996, 94(9 Suppl.):II389-II397.
29. Wang P., Gallagher K.P., Downey J.M., Cohen M.V. Pretreatment with endothelin-1 mimics ischemic preconditioning against infarction in isolated rabbit heart. J Mol Cell Cardiol 1996, 28(3):579-588.
30. Erikson J.M., Velasco C.E. Endothelin-1 and myocardial preconditioning. Am Heart J 1996, 132(1 Pt 1):84-90.
31. Wirth K.J., Linz W., Wiemer G., Scholkens B.A. Kinins and cardioprotection. Pharmacol Res 1997, 35(6):527-530.
32. Minshall R.D., Nakamura F., Becker R.P., Rabito S.F. Characterization of bradykinin B2 receptors in adult myocardium and neonatal rat cardiomyocytes. Circ Res 1995, 76(5):773-780.
33. Wall T.M., Sheehy R., Hartman J.C. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 1994, 270(2):681-689.
34. Bell R.M., Yellon D.M. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 2003, 35(2):185-193.
35. Parratt J.R., Vegh A., Zeitlin I.J., Ahmad M., Oldroyd K., Kaszala K., et al. Bradykinin and endothelial-cardiac myocyte interactions in ischemic preconditioning. Am J Cardiol 1997, 80(3A):124A-131A.
36. Liu X., Lukasova M., Zubakova R., Lewicka S., Hilgenfeldt U. Kallidin-like peptide mediates the cardioprotective effect of the ACE inhibitor captopril against ischaemic reperfusion injury of rat heart. Br J Pharmacol 2006, 148(6):825-832.
37. Liu X., Lukasova M., Zubakova R., Lewicka S., Hilgenfeldt U. A kallidin-like peptide is a protective cardiac kinin, released by ischaemic preconditioning of rat heart. Br J Pharmacol 2005, 146(7):952-957.
38. Bouchard J.F., Chouinard J., Lamontagne D. Participation of prostaglandin E2 in the endothelial protective effect of ischaemic preconditioning in isolated rat heart. Cardiovasc Res 2000, 45(2):418-427.
39. Hedhli N., Huang Q., Kalinowski A., Palmeri M., Hu X., Russell R.R., et al. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation 2011, 123(20):2254-2262.
40. Bell R.M., Yellon D.M. The contribution of endothelial nitric oxide synthase to early ischaemic preconditioning: the lowering of the preconditioning threshold. An investigation in eNOS knockout mice. Cardiovasc Res 2001, 52(2):274-280.
41. Bell R.M., Yellon D.M. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003, 41(3):508-515.
42. Turek Z., Grandtner M., Kubat K., Ringnalda B.E., Kreuzer F. Arterial blood gases, muscle fiber diameter and intercapillary distance in cardiac hypertrophy of rats with an old myocardial infarction. Pflugers Arch 1978, 376(3):209-215.
43. Lancaster J.R. Diffusion of free nitric oxide. Methods Enzymol 1996, 268:31-50.
44. Ohtani H., Katoh H., Tanaka T., Saotome M., Urushida T., Satoh H., et al. Effects of nitric oxide on mitochondrial permeability transition pore and thiol-mediated responses in cardiac myocytes. Nitric Oxide 2011, 26(2):95-101.
45. Hansen P.R. Inflammatory alterations in the myocardial microcirculation. J Mol Cell Cardiol 1998, 30(12):2555-2559.
46. Seal J.B., Gewertz B.L. Vascular dysfunction in ischemia-reperfusion injury. Ann Vasc Surg 2005, 19(4):572-584.
47. Kikuchi G., Yoshida T., Noguchi M. Heme oxygenase and heme degradation. Biochem Biophys Res Commun 2005, 338(1):558-567.
48. Hangaishi M., Ishizaka N., Aizawa T., Kurihara Y., Taguchi J., Nagai R., et al. Induction of heme oxygenase-1 can act protectively against cardiac ischemia/reperfusion in vivo. Biochem Biophys Res Commun 2000, 279(2):582-588.
49. Yet S.F., Tian R., Layne M.D., Wang Z.Y., Maemura K., Solovyeva M., et al. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res 2001, 89(2):168-173.
50. Wang G., Hamid T., Keith R.J., Zhou G., Partridge C.R., Xiang X., et al. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation. 2010, 121(17):1912-1925.
51. Peers C., Steele D.S. Carbon monoxide: a vital signalling molecule and potent toxin in the myocardium. J Mol Cell Cardiol 2012, 52(2):359-365.
52. Elrod J.W., Calvert J.W., Morrison J., Doeller J.E., Kraus D.W., Tao L., et al. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A 2007, 104(39):15560-15565.
53. Calvert J.W., Jha S., Gundewar S., Elrod J.W., Ramachandran A., Pattillo C.B., et al. Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res 2009, 105(4):365-374.
54. Predmore B.L., Lefer D.J. Hydrogen sulfide-mediated myocardial pre- and post-conditioning. Expert Rev Clin Pharmacol 2011, 4(1):83-96.
55. Hu Y., Chen X., Pan T.T., Neo K.L., Lee S.W., Khin E.S., et al. Cardioprotection induced by hydrogen sulfide preconditioning involves activation of ERK and PI3K/Akt pathways. Pflugers Arch 2008, 455(4):607-616.
56. Yao L.L., Huang X.W., Wang Y.G., Cao Y.X., Zhang C.C., Zhu Y.C. Hydrogen sulfide protects cardiomyocytes from hypoxia/reoxygenation-induced apoptosis by preventing GSK-3beta-dependent opening of mPTP. Am J Physiol 2010, 298(5):H1310-H1319.
57. Nicholson C.K., Calvert J.W. Hydrogen sulfide and ischemia-reperfusion injury. Pharmacol Res 2010, 62(4):289-297.
58. Shirai T., Rao V., Weisel R.D., Ikonomidis J.S., Li R.K., Tumiati L.C., et al. Preconditioning human cardiomyocytes and endothelial cells. J Thorac Cardiovasc Surg 1998, 115(1):210-219.
59. Richard V., Blanc T., Kaeffer N., Tron C., Thuillez C. Myocardial and coronary endothelial protective effects of acetylcholine after myocardial ischaemia and reperfusion in rats: role of nitric oxide. Br J Pharmacol 1995, 115(8):1532-1538.
60. Giannella E., Mochmann H.C., Levi R. Ischemic preconditioning prevents the impairment of hypoxic coronary vasodilatation caused by ischemia/reperfusion: role of adenosine A1/A3 and bradykinin B2 receptor activation. Circ Res 1997, 81(3):415-422.
61. Kuzner J., Drevensek G., Gersak B., Budihna M. Hypoxic and pharmacological preconditioning preserves vasomotor response of porcine coronary artery. Pol J Pharmacol 2004, 56(6):789-797.
62. Kloner R.A., Ganote C.E., Jennings R.B. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974, 54(6):1496-1508.
63. Kleinbongard P., Konorza T., Bose D., Baars T., Haude M., Erbel R., et al. Lessons from human coronary aspirate. J Mol Cell Cardiol 2012, 52(4):890-896.
64. Iwakura K., Ito H., Kawano S., Shintani Y., Yamamoto K., Kato A., et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol 2001, 38(2):472-477.
65. Bauer B., Simkhovich B.Z., Kloner R.A., Przyklenk K. Does preconditioning protect the coronary vasculature from subsequent ischemia/reperfusion injury?. Circulation 1993, 88(2):659-672.
66. Jerome S.N., Akimitsu T., Gute D.C., Korthuis R.J. Ischemic preconditioning attenuates capillary no-reflow induced by prolonged ischemia and reperfusion. Am J Physiol 1995, 268(5 Pt 2):H2063-H2067.
67. Zhao J.L., Yang Y.J., You S.J., Cui C.J., Gao R.L. Different effects of postconditioning on myocardial no-reflow in the normal and hypercholesterolemic mini-swines. Microvasc Res 2007, 73(2):137-142.
68. Zhao J.L., Yang Y.J., Pei W.D., Sun Y.H., You S.J., Gao R.L. Remote periconditioning reduces myocardial no-reflow by the activation of K ATP channel via inhibition of Rho-kinase. Int J Cardiol 2009, 133(2):179-184.
69. Jaffe R., Dick A., Strauss B.H. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach. Jacc 2011, 3(7):695-704.
70. Riksen N.P., Hausenloy D.J., Yellon D.M. Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 2008, 29(5):258-267.
71. Niccoli G., Andreotti F., Marzo F., Cecchetti S., Santucci E., D'Amario D., et al. Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction. Eur J Clin Invest 2011, 41:1210-1219.
72. Ludman A.J., Yellon D.M., Hasleton J., Ariti C., Babu G.G., Boston-Griffiths E., et al. Effect of erthropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart 2011, 97:1560-1565.
73. Souders C.A., Bowers S.L., Baudino T.A. Cardiac fibroblast: the renaissance cell. Circ Res 2009, 105(12):1164-1176.
74. Camelliti P., Green C.R., Kohl P. Structural and functional coupling of cardiac myocytes and fibroblasts. Adv Cardiol 2006, 42:132-149.
75. Dostal D.E., Rothblum K.N., Chernin M.I., Cooper G.R., Baker K.M. Intracardiac detection of angiotensinogen and renin: a localized renin-angiotensin system in neonatal rat heart. Am J Physiol 1992, 263(4 Pt 1):C838-C850.
76. Kuwahara K., Saito Y., Harada M., Ishikawa M., Ogawa E., Miyamoto Y., et al. Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro. Circulation 1999, 100(10):1116-1124.
77. Tomoda Y., Kikumoto K., Isumi Y., Katafuchi T., Tanaka A., Kangawa K., et al. Cardiac fibroblasts are major production and target cells of adrenomedullin in the heart in vitro. Cardiovasc Res 2001, 49(4):721-730.
78. Farivar R.S., Chobanian A.V., Brecher P. Salicylate or aspirin inhibits the induction of the inducible nitric oxide synthase in rat cardiac fibroblasts. Circ Res 1996, 78(5):759-768.
79. Lakkisto P., Palojoki E., Backlund T., Saraste A., Tikkanen I., Voipio-Pulkki L.M., et al. Expression of heme oxygenase-1 in response to myocardial infarction in rats. J Mol Cell Cardiol 2002, 34(10):1357-1365.
80. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 2001, 33(11):1897-1918.
81. Htun P., Ito W.D., Hoefer I.E., Schaper J., Schaper W. Intramyocardial infusion of FGF-1 mimics ischemic preconditioning in pig myocardium. J Mol Cell Cardiol 1998, 30(4):867-877.
82. Jiang Z.S., Wen G.B., Tang Z.H., Srisakuldee W., Fandrich R.R., Kardami E. High molecular weight FGF-2 promotes postconditioning-like cardioprotection linked to activation of protein kinase C isoforms, as well as Akt and p70 S6 kinases. Can J Physiol Pharmacol 2009, 87(10):798-804. [corrected].
83. Martire A., Fernandez B., Buehler A., Strohm C., Schaper J., Zimmermann R., et al. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice mimics ischemic preconditioning through SAPK/JNK1/2 activation. Cardiovasc Res 2003, 57(2):523-534.
84. House S.L., Bolte C., Zhou M., Doetschman T., Klevitsky R., Newman G., et al. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation 2003, 108(25):3140-3148.
85. Kardami E., Detillieux K., Ma X., Jiang Z., Santiago J.J., Jimenez S.K., et al. Fibroblast growth factor-2 and cardioprotection. Heart Fail Rev 2007, 12(3-4):267-277.
86. Nakazato K., Naganuma W., Ogawa K., Yaoita H., Mizuno S., Nakamura T., et al. Attenuation of ischemic myocardial injury and dysfunction by cardiac fibroblast-derived factor(s). Fukushima J Med Sci 2010, 56(1):1-16.
87. Matsunaga S., Okigaki M., Takeda M., Matsui A., Honsho S., Katsume A., et al. Endothelium-targeted overexpression of constitutively active FGF receptor induces cardioprotection in mice myocardial infarction. J Mol Cell Cardiol 2009, 46(5):663-673.
88. Kawaguchi M., Takahashi M., Hata T., Kashima Y., Usui F., Morimoto H., et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011, 123(6):594-604.
89. Baum J., Duffy H.S. Fibroblasts and myofibroblasts: what are we talking about?. J Cardiovasc Pharmacol 2011, 57(4):376-379.
90. Sundset R., Cooper M., Mikalsen S.O., Ytrehus K. Ischemic preconditioning protects against gap junctional uncoupling in cardiac myofibroblasts. Cell Commun Adhes 2004, 11(2-4):51-66.
91. Cooper M., Ytrehus K. Cell survival signalling in heart derived myofibroblasts induced by preconditioning and bradykinin: the role of p38 MAP kinase. Mol Cell Biochem 2004, 259(1-2):83-90.
92. Hagar J.M., Hale S.L., Kloner R.A. Effect of preconditioning ischemia on reperfusion arrhythmias after coronary artery occlusion and reperfusion in the rat. Circ Res 1991, 68(1):61-68.
93. Shiki K., Hearse D.J. Preconditioning of ischemic myocardium: reperfusion-induced arrhythmias. Am J Physiol 1987, 253(6 Pt 2):H1470-H1476.
94. Vanhoutte D., Heymans S. TIMPs and cardiac remodeling: 'embracing the MMP-independent-side of the family'. J Mol Cell Cardiol 2010, 48(3):445-453.
95. Dobaczewski M., Gonzalez-Quesada C., Frangogiannis N.G. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol Mar 2010, 48(3):504-511.
96. Vilahur G., Juan-Babot O., Pena E., Onate B., Casani L., Badimon L. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol Mar 2011, 50(3):522-533.
97. Nilsson L., Hallen J., Atar D., Jonasson L., Swahn E. Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction. Heart 2012, 98:31-36.
98. Williams-Pritchard G., Knight M., Hoe L.S., Headrick J.P., Peart J.N. Essential role of EGFR in cardioprotection and signaling responses to A1 adenosine receptors and ischemic preconditioning. Am J Physiol 2011, 300(6):H2161-8.
99. Methner C., Donat U., Felix S.B., Krieg T. Cardioprotection of bradykinin at reperfusion involves transactivation of the epidermal growth factor receptor via matrix metalloproteinase-8. Acta Physiol (Oxf) 2009, 197(4):265-271.
100. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14(2):163-176.
101. Hausenloy D.J., Yellon D.M. Cardioprotective growth factors. Cardiovasc Res 2009, 83(2):179-194.
102. Moshal K.S., Tyagi N., Henderson B., Ovechkin A.V., Tyagi S.C. Protease-activated receptor and endothelial-myocyte uncoupling in chronic heart failure. Am J Physiol 2005, 288(6):H2770-H2777.
103. Cheung P.Y., Sawicki G., Wozniak M., Wang W., Radomski M.W., Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000, 101(15):1833-1839.
104. Sawicki G., Leon H., Sawicka J., Sariahmetoglu M., Schulze C.J., Scott P.G., et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 2005, 112(4):544-552.
105. Sung M.M., Schulz C.G., Wang W., Sawicki G., Bautista-Lopez N.L., Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol 2007, 43(4):429-436.
106. Ali M.A., Cho W.J., Hudson B., Kassiri Z., Granzier H., Schulz R. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation 2010, 122(20):2039-2047.
107. Bencsik P., Kupai K., Giricz Z., Gorbe A., Pipis J., Murlasits Z., et al. Role of iNOS and peroxynitrite-matrix metalloproteinase-2 signaling in myocardial late preconditioning in rats. Am J Physiol 2010, 299(2):H512-8.
108. Giricz Z., Lalu M.M., Csonka C., Bencsik P., Schulz R., Ferdinandy P. Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition. J Pharmacol Exp Ther 2006, 316(1):154-161.
109. Romero-Perez D., Fricovsky E., Yamasaki K.G., Griffin M., Barraza-Hidalgo M., Dillmann W., et al. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol 2008, 52(13):1086-1094.
110. Xin W., Yang X., Rich T.C., Krieg T., Barrington R., Cohen M.V., et al. All preconditioning-related G protein-coupled receptors can be demonstrated in the rabbit cardiomyocyte. J Cardiovasc Pharmacol Ther 2012, 17:190-198.
111. Safran N., Shneyvays V., Balas N., Jacobson K.A., Nawrath H., Shainberg A. Cardioprotective effects of adenosine A1 and A3 receptor activation during hypoxia in isolated rat cardiac myocytes. Mol Cell Biochem 2001, 217(1-2):143-152.
112. Wu S., Li H.Y., Wong T.M. Cardioprotection of preconditioning by metabolic inhibition in the rat ventricular myocyte. Involvement of kappa-opioid receptor. Circ Res 1999, 84(12):1388-1395.
113. Pan T.T., Feng Z.N., Lee S.W., Moore P.K., Bian J.S. Endogenous hydrogen sulfide contributes to the cardioprotection by metabolic inhibition preconditioning in the rat ventricular myocytes. J Mol Cell Cardiol 2006, 40(1):119-130.
114. Kempf T., Eden M., Strelau J., Naguib M., Willenbockel C., Tongers J., et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006, 98(3):351-360.
115. Hu X., Dai S., Wu W.J., Tan W., Zhu X., Mu J., et al. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation 2007, 116(6):654-663.
116. Wang Y., Lau W.B., Gao E., Tao L., Yuan Y., Li R., et al. Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury. Am J Physiol Endocrinol Metab 2011, 298(3):E663-E670.
117. Wang Y., Guo Y., Zhang S.X., Wu W.J., Wang J., Bao W., et al. Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiac myocyte. J Mol Cell Cardiol 2002, 34(1):5-15.